Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Cancer Res Treat. 2023 Jan;55(1):103-111. doi: 10.4143/crt.2022.264. Epub 2022 Jun 20.
This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.
The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.
We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non-small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).
In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.
本研究旨在提供 2015 年诊断的肺癌的临床特征、预后因素和 5 年相对生存率。
2015 年，使用韩国肺癌登记处（KALC-R）队列计算肺癌的人口统计学风险因素，生存随访至 2020 年 12 月 31 日。使用 Ederer II 方法估计 5 年相对生存率，一般人群数据使用 2015 年至 2020 年韩国统计信息服务公布的按性别和年龄调整的死亡率。
我们纳入了 2015 年在韩国诊断的 2657 例肺癌患者。所有患者中，2098 例（79.0%）诊断为非小细胞肺癌（NSCLC），345 例（13.0%）诊断为小细胞肺癌（SCLC）。年龄较大、一般状况较差和临床晚期是 NSCLC 和 SCLC 的独立危险因素。此外，在 NSCLC（82%、59%、16%、10%随着分期进展）和 SCLC（16%、4%随着分期进展）中，5 年相对生存率随着分期进展而下降。在 IV 期腺癌患者中，表皮生长因子受体（EGFR）突变（19%比 11%）或间变性淋巴瘤激酶（ALK）易位（38%比 11%）存在时，5 年相对生存率更高。
在这项韩国全国性调查中，I 期 NSCLC 的 5 年相对生存率为 82%，II 期为 59%，III 期为 16%，IV 期为 10%，SCLC 的 5 年相对生存率为局限期为 16%，广泛期为 4%。
